Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00606645 · ClinicalTrials.gov registry record · Phase 1
Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma
A Phase 1 study of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma, sponsored by Xencor.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
- 4
- Study locations
NCT00606645 is a Phase 1 study of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma that has completed, run by Xencor. The registered enrollment target is 23 participants, below the 166-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (86% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT00606645, a Phase 1 study of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma, has completed, sponsored by Xencor.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
- 4
- Study locations
Study Summary
An open-label, multi-dose, single-arm, Phase 1 dose escalation study of XmAb®2513 was conducted to define the MTD or recommended dose(s) for further study, to determine safety and tolerability, to characterize PK and immunogenicity, and to evaluate antitumor activity of XmAb2513 in patients with HL and ALCL (non-cutaneous) and who have received two or more prior therapeutic regimens. There will be no intra-patient dose escalation.
Conditions Studied
Interventions
- BIOLOGICAL XmAb2513
Study Locations (4)
Illinois
- Rush University Medical Center - Chicago
Ohio
- Ohio State University - Columbus
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2007-12 |
| Est. Completion | 2010-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00606645
The ClinicalTrials.gov registry entry for NCT00606645 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 166-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (86% lower). The listed sponsor is Xencor, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hodgkin Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which XmAb2513 is the first listed.
NCT00606645 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Illinois, Ohio, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00606645 about?
NCT00606645 is a clinical study titled "Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma". An open-label, multi-dose, single-arm, Phase 1 dose escalation study of XmAb®2513 was conducted to define the MTD or recommended dose(s) for further study, to determine safety and tolerability, to characterize PK and immunogenicity, and to evaluate antitumor activity of XmAb2513 in patients with HL ...
What is the current status of trial NCT00606645?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2007-12. Estimated completion is 2010-04.
What conditions does trial NCT00606645 study?
This clinical trial studies the following conditions: Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma.
What interventions are being tested in trial NCT00606645?
The interventions under investigation include: XmAb2513 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00606645?
This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00606645 being conducted?
This trial has 4 study locations across Illinois, Ohio, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
RECRUITING · Phase 1
-
AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.
RECRUITING · Phase 1
-
ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells
RECRUITING · Phase 1
-
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.